Rollins Q1 2026 slides: sequential growth accelerates into peak season

Rollins reported Q1 2026 revenue of $906.4 million and adjusted EPS of $0.24, both ahead of consensus, with revenue up 10.2% year over year and March organic growth accelerating to over 8%. Adjusted EBITDA margin compressed 110 bps to 19.8%, but management guided to 7-8% organic growth, 9-11% total growth, and 25-30% full-year adjusted incremental EBITDA margins. The company also announced the acquisition of Romex Pest Control and continued strong capital returns, including $88 million in dividends.

Analysis

The key read-through is not the earnings beat itself but the shape of the cycle: this is a high-quality defensive compounder entering its strongest demand window with capacity already funded. That matters because service businesses with recurring routes tend to re-rate when investors see margin compression as temporary rather than structural; the current setup suggests the quarter’s cost drag is more of a timing issue than an earnings power reset. The second-order winner is likely local labor and route density acquisition, as larger players with balance-sheet flexibility can use peak-season staffing and M&A to widen the gap versus smaller regional operators that cannot absorb insurance and claims volatility as easily.

The market may be underestimating how quickly operating leverage can snap back over the next 1-2 quarters. If volume inflects into peak season while incremental SG&A gets absorbed, earnings power can accelerate disproportionately versus revenue, and that typically drives multiple expansion in names already near cycle lows. The main risk is that insurance and claims costs remain sticky longer than management expects, in which case margin recovery is delayed and the stock could stay rangebound despite good reported growth.

Contrarian angle: consensus is probably treating this as a slow-and-steady defensive name, but the combination of sub-1x leverage, >100% cash conversion, and ongoing tuck-in acquisition capacity makes this more of a capital-allocation story than a pure organic-growth story. The implied upside is not from heroic earnings estimates; it is from steady execution plus the market paying up for durability once peak-season data confirms the margin inflection. If the next monthly checks show March-like acceleration holding into the summer, the rerating could happen faster than expected.

Key Decisions for Investors

• Go long ROL into peak-season confirmation over the next 4-8 weeks; target a re-rating as investors price in Q2/Q3 margin recovery. Risk/reward favors 10-15% upside if operating leverage normalizes, with downside limited by defensive cash flow and balance-sheet strength.
• Buy ROL call spreads out 2-4 months to express a tactical seasonal trade with defined risk. Favor structures that monetize a modest rerating rather than a large earnings revision, since the stock may gap on margin commentary before full-year numbers change.
• Pair long ROL vs short a lower-quality regional pest/home-services operator basket over 1-2 quarters. The thesis is that scale, acquisition capacity, and pricing discipline should widen the performance gap if labor and insurance costs stay volatile.
• If ROL pulls back on near-term margin noise, add on weakness rather than chasing strength. The setup improves if shares remain closer to the 52-week low than the high despite sequential monthly acceleration, because that implies the market is still discounting a recovery that could arrive quickly.